NS3


Also found in: Acronyms.

NS3

Abbreviation for:
Noonan syndrome type 3 (see there)
References in periodicals archive ?
NS2 also appears to be involved in a particle assembly step which happens post core, NS5A, and NS3 assembly (75).
At a liver-disease meeting in Boston this week, scientists from two other drug companies described initial cell and animal tests of their own NS3 inhibitors.
Asunaprevir is an NS3 protease inhibitor in Phase III development for hepatitis C as a component of daclatasvir-based treatment regimens, and has been studied in more than 1,200 patients to date.
Studies on NS3 region of HGV have been reported from the Spain, Germany, China, USA and UK (21-24).
The ORTHO ELISA III detects antibodies directed to core, nonstructural 3 (NS3), NS4, and NS5 antigens; the MONOLISA anti-HCV plus detects antibodies directed to core, NS3, and NS4 antigens.
BOSTON -- Bristol-Myers Squibb Company (NYSE: BMY) today announced new Phase II data demonstrating that the dual regimen of the investigational NS5A replication complex inhibitor daclatasvir (DCV) and the investigational NS3 protease inhibitor asunaprevir (ASV), without interferon or ribavirin, achieved high rates of sustained virologic response 12 weeks post-treatment (SVR12) in patients with genotype 1b (GT1b) hepatitis C virus (HCV) who were prior null responders to alfa interferon and ribavirin (alfa/RBV).
orally available combination therapies based on the NS5A inhibitor daclatasvir, the NS3 protease inhibitor asunaprevir and the non-nucleoside inhibitor of HCV NS5B
Before treatment, clinicians should screen patients with genotype la HCV infections for the presence of the NS3 Q80K polymorphism, which was asso-dated with lower response rates in studies, "and to consider alternative therapy if the strain is detected," according to the FDA.
The PCR was specific for conserved sequences in the 5' untranslated region (5'-UTR) and the NS3 regions of NPHV.
BOSTON -- Bristol-Myers Squibb Company (NYSE: BMY) today announced new Phase II data demonstrating that an investigational quad therapy regimen combining the NS5A replication complex inhibitor daclatasvir (DCV), the NS3 protease inhibitor asunaprevir (ASV), and a backbone of alfa interferon and ribavirin (alfa/RBV) achieved sustained virologic response rates 12- and 24-weeks post-treatment (SVR12 and SVR24) of 95% (39/41) and 93% (38/41), respectively, in patients with genotype 1 (GT1) hepatitis C virus (HCV) who were prior null responders to alfa/RBV.
SVR12 rates of 100 percent were seen among patients with IL28B CC genotype (n=43/43) and those with baseline NS5A and NS3 Q80K polymorphisms (n=9/9).
The European Broa dcasting Union plans to upgrade its European satellite network with third generation NovelSat NS3 transmission technology